Zacks: Brokerages Anticipate Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Will Announce Earnings of $0.20 Per Share

Brokerages expect that Tandem Diabetes Care, Inc. (NASDAQ:TNDM) will report $0.20 earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for Tandem Diabetes Care’s earnings. The lowest EPS estimate is $0.16 and the highest is $0.27. Tandem Diabetes Care reported earnings per share of $0.24 in the same quarter last year, which would suggest a negative year-over-year growth rate of 16.7%. The firm is expected to announce its next earnings report on Wednesday, February 23rd.

On average, analysts expect that Tandem Diabetes Care will report full-year earnings of $0.31 per share for the current fiscal year, with EPS estimates ranging from $0.24 to $0.37. For the next year, analysts forecast that the firm will report earnings of $0.81 per share, with EPS estimates ranging from $0.45 to $1.06. Zacks’ earnings per share averages are an average based on a survey of analysts that cover Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, November 3rd. The medical device company reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.01. The company had revenue of $179.63 million for the quarter, compared to the consensus estimate of $172.80 million. Tandem Diabetes Care had a net margin of 3.29% and a return on equity of 6.85%. During the same quarter in the prior year, the firm earned ($0.09) earnings per share.

A number of equities research analysts recently issued reports on TNDM shares. Wells Fargo & Company upped their price target on shares of Tandem Diabetes Care from $121.00 to $137.00 and gave the company an “equal weight” rating in a research note on Thursday, November 4th. Raymond James boosted their price objective on shares of Tandem Diabetes Care from $120.00 to $138.00 and gave the company an “outperform” rating in a research report on Thursday, November 4th. SVB Leerink boosted their price objective on shares of Tandem Diabetes Care from $135.00 to $140.00 and gave the company a “market perform” rating in a research report on Thursday, November 4th. Lake Street Capital boosted their price objective on shares of Tandem Diabetes Care from $165.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, December 7th. Finally, Piper Sandler boosted their price objective on shares of Tandem Diabetes Care from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Monday, December 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of “Buy” and a consensus price target of $141.89.

Tandem Diabetes Care stock opened at $120.76 on Friday. The company has a market cap of $7.67 billion, a price-to-earnings ratio of 416.41 and a beta of 0.40. The firm’s fifty day moving average is $137.87 and its 200 day moving average is $123.04. The company has a quick ratio of 5.76, a current ratio of 6.31 and a debt-to-equity ratio of 0.72. Tandem Diabetes Care has a 52-week low of $76.19 and a 52-week high of $155.86.

In other Tandem Diabetes Care news, SVP James Leal sold 1,906 shares of the stock in a transaction dated Monday, December 27th. The shares were sold at an average price of $151.45, for a total transaction of $288,663.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David B. Berger sold 1,000 shares of the stock in a transaction dated Monday, January 3rd. The shares were sold at an average price of $149.16, for a total transaction of $149,160.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,382 shares of company stock worth $10,537,730. Company insiders own 4.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. lifted its position in shares of Tandem Diabetes Care by 5.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,800 shares of the medical device company’s stock valued at $273,000 after buying an additional 141 shares during the last quarter. Virginia Retirement Systems ET AL raised its position in shares of Tandem Diabetes Care by 49.5% in the 2nd quarter. Virginia Retirement Systems ET AL now owns 13,600 shares of the medical device company’s stock valued at $1,325,000 after purchasing an additional 4,500 shares during the last quarter. Deutsche Bank AG raised its position in shares of Tandem Diabetes Care by 17.4% in the 3rd quarter. Deutsche Bank AG now owns 146,330 shares of the medical device company’s stock valued at $17,469,000 after purchasing an additional 21,659 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Tandem Diabetes Care by 2,741.5% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 38,701 shares of the medical device company’s stock valued at $3,769,000 after purchasing an additional 37,339 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund purchased a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $2,518,000. 95.58% of the stock is owned by institutional investors and hedge funds.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Featured Article: Price-Sales Ratio

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.